30 April 2020 
EMA/207923/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Kalydeco 
ivacaftor 
On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Kalydeco. The marketing authorisation holder for this medicinal product is Vertex Pharmaceuticals 
(Ireland) Limited. 
The CHMP adopted a change to the indication for Kalydeco tablets as follows:2 
Kalydeco tablets are indicated for the treatment of adults, adolescents, and children aged 6 years 
and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR 
mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, 
G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1). 
Kalydeco tablets are also indicated for the treatment of adults, adolescents, and children aged 
18 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H 
mutation in the CFTR gene (see sections 4.4 and 5.1). 
Kalydeco tablets are also indicated in a combination regimen with tezacaftor 100 mg/ivacaftor 
150 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic 
fibrosis (CF) who are homozygous for the F508del mutation or who are heterozygous for the 
F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, 
L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 
3272 26A→G, and 3849+10kbC→T. 
The CHMP also adopted a change to the indication for Kalydeco granules as follows: 
Kalydeco granules are indicated for the treatment of infants aged at least 6 months, toddlers and 
children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR 
mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, 
G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Kalydeco  
EMA/207923/2020 
Page 2/2 
 
  
  
 
